BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile
..
 

InterMune, Inc. 

3280 Bayshore Boulevard

Brisbane  California  94005  U.S.A.
Phone: 415-466-2200 Fax: 415-466-2329


SEARCH JOBS
InterMune is a biotechnology company focused on the research, development and commercialization of innovative therapies in pulmonology and hepatology. InterMune has a product portfolio addressing IPF and HCV infections. The pulmonology portfolio includes Actimmune®, which is being evaluated in the INSPIRE Trial, a Phase III study in patients with IPF, and pirfenidone, which is also being developed for the treatment of IPF. The hepatology portfolio includes the lead HCV protease inhibitor compound (ITMN B), a second-generation HCV protease inhibitor program, and a research program evaluating a new target in hepatology.

For additional information about InterMune and its R&D pipeline, please visit: www.intermune.com


 Key Statistics


Email:
Ownership: Public

Web Site: InterMune, Inc.
Employees:
Symbol: ITMN
 




Segment
Drug Discovery





 Company News
Bay Area's InterMune, Inc. (ITMN) Gains As Boehringer Ingelheim Corporation's Rival Drug Shows Mixed Results 3/24/2014 8:19:00 AM    More...
InterMune, Inc. (ITMN) Announces Pricing Of Public Offering Of 7,500,000 Shares Of Common Stock 3/14/2014 10:46:23 AM    More...
Bay Area's InterMune, Inc. (ITMN) Hits A Home Run With Pivotal Phase 3 Lung Drug Study Results; Stock Rockets 2/25/2014 7:11:55 AM    More...
InterMune, Inc. (ITMN) Reports Preliminary Fourth Quarter 2013 Esbriet® (pirfenidone) Revenue And Recent Business Highlights 1/9/2014 6:44:03 AM    More...
InterMune, Inc. (ITMN) To Present At J. P. Morgan Healthcare Conference 1/6/2014 6:30:53 AM    More...
U.S. Supreme Court Refuses To Hear Ex-InterMune, Inc. (ITMN) CEO's Appeal 12/16/2013 8:13:13 AM    More...
European Court May Force AbbVie (ABBV), InterMune, Inc. (ITMN) To Release Business Secrets 12/6/2013 6:39:47 AM    More...
InterMune, Inc. (ITMN) Announces Pricing of Public Offering of 6,500,000 Shares of Common Stock 11/6/2013 10:05:28 AM    More...
InterMune, Inc. (ITMN) Announces Proposed Public Offering of Common Stock 11/5/2013 8:10:43 AM    More...
InterMune, Inc. (ITMN) Reports Third Quarter 2013 Financial Results and Business Highlights 10/31/2013 6:51:38 AM    More...
12345678910...

//-->